MIRA Pharmaceuticals, Inc. Common Stock (MIRA) is a Healthcare · Drug Manufacturers - General company listed on NASDAQ. Price $0.79 (+4.46%), Market cap $0.04B, 52-week low–high $0.92 ~ $2.02.
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA
Financial statements, price targets, institutional (13F) holdings and related news for MIRA Pharmaceuticals, Inc. Common Stock are updated in real time on BlackAll Trade.
MIRA Pharmaceuticals, Inc. Common Stock trades at $0.79 (+4.46%). Real-time quotes and charts are available on BlackAll Trade.
MIRA Pharmaceuticals, Inc. Common Stock has a market cap of about $0.04B.
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The compan